Market overview
The global extended-action local anaesthetic market is worth USD 684 mn in 2026 and is forecast to reach USD 1.4 bn by 2036, growing at a 7.5% CAGR. United States is the largest country market and Liposomal bupivacaine is the largest by product segment.
| Scope | Long-acting local anaesthetics that give 24 to 72 hours of post-surgical pain relief from a single dose, including liposomal bupivacaine, extended-release bupivacaine and bupivacaine implants. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 630 mn |
| Value 2026 | USD 684 mn |
| Value 2036 | USD 1.4 bn |
| CAGR 2026-2036 | 7.5% |
| Volume 2026 | 3.44 million doses |
| Volume 2036 | 6.41 million doses |
| Average price 2026 | USD 199 per dose |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Extended-Action Local Anaesthetic market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 683.5 mn |
| 2027 | USD 734.8 mn |
| 2028 | USD 789.9 mn |
| 2029 | USD 849.2 mn |
| 2030 | USD 912.9 mn |
| 2031 | USD 981.3 mn |
| 2032 | USD 1.05 bn |
| 2033 | USD 1.13 bn |
| 2034 | USD 1.22 bn |
| 2035 | USD 1.31 bn |
| 2036 | USD 1.41 bn |
Extended-Action Local Anaesthetic market segmentation
By product
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Liposomal bupivacaine | 86.0% | 45.4% | USD 588 mn | 0.8% |
| Extended-release bupivacaine and meloxicam | 9.0% | 50.9% | USD 62 mn | 27.8% |
| Bupivacaine implants and others | 5.0% | 3.6% | USD 34 mn | 4.2% |
By setting
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospitals | 50.0% | 44.4% | USD 342 mn | 6.2% |
| Ambulatory surgery centres | 42.0% | 47.0% | USD 287 mn | 8.7% |
| Specialty surgical hospitals | 8.0% | 8.6% | USD 55 mn | 8.2% |
By surgery
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Orthopaedic | 46.0% | 44.1% | USD 314 mn | 7.0% |
| General and abdominal | 24.0% | 24.1% | USD 164 mn | 7.5% |
| Cardiothoracic and plastic | 18.0% | 19.8% | USD 123 mn | 8.5% |
| Other surgery | 12.0% | 12.0% | USD 82 mn | 7.5% |
By administration
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Surgical-site infiltration | 52.0% | 46.0% | USD 355 mn | 6.2% |
| Peripheral nerve block | 34.0% | 38.0% | USD 232 mn | 8.7% |
| Epidural and implant-based | 14.0% | 16.0% | USD 96 mn | 8.9% |
By payer
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Commercial insurance | 52.0% | 50.0% | USD 355 mn | 7.1% |
| Medicare | 36.0% | 38.0% | USD 246 mn | 8.1% |
| Medicaid and self-pay | 12.0% | 12.0% | USD 82 mn | 7.5% |
Top 25 countries for extended-action local anaesthetic by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 98.7% of 2026 revenue and the 25 countries below together hold 99.6%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 649 mn | 95.0% | USD 1.3 bn | 7.3% |
| 2 | Germany | USD 6.8 mn | 1.0% | USD 21 mn | 11.9% |
| 3 | United Kingdom | USD 5.5 mn | 0.8% | USD 17 mn | 11.9% |
| 4 | France | USD 3.4 mn | 0.5% | USD 9.9 mn | 11.2% |
| 5 | Spain | USD 2.0 mn | 0.3% | USD 5.6 mn | 10.6% |
| 6 | Italy | USD 2.0 mn | 0.3% | USD 5.6 mn | 10.6% |
| 7 | Japan | USD 1.4 mn | 0.2% | USD 4.2 mn | 11.9% |
| 8 | Canada | USD 1.4 mn | 0.2% | USD 4.2 mn | 11.9% |
| 9 | Australia | USD 1.4 mn | 0.2% | USD 4.2 mn | 11.9% |
| 10 | Netherlands | USD 1.4 mn | 0.2% | USD 4.2 mn | 11.9% |
| 11 | China | USD 0.82 mn | 0.1% | USD 2.1 mn | 9.9% |
| 12 | Brazil | USD 0.48 mn | 0.07% | USD 1.1 mn | 8.9% |
| 13 | Switzerland | USD 0.48 mn | 0.07% | USD 0.85 mn | 5.9% |
| 14 | Belgium | USD 0.48 mn | 0.07% | USD 0.85 mn | 5.9% |
| 15 | Sweden | USD 0.48 mn | 0.07% | USD 0.85 mn | 5.9% |
| 16 | South Korea | USD 0.48 mn | 0.07% | USD 1.1 mn | 8.9% |
| 17 | Austria | USD 0.41 mn | 0.06% | USD 0.70 mn | 5.6% |
| 18 | Denmark | USD 0.41 mn | 0.06% | USD 0.70 mn | 5.6% |
| 19 | Israel | USD 0.41 mn | 0.06% | USD 0.70 mn | 5.6% |
| 20 | Saudi Arabia | USD 0.41 mn | 0.06% | USD 0.85 mn | 7.5% |
| 21 | Ireland | USD 0.27 mn | 0.04% | USD 0.56 mn | 7.5% |
| 22 | Norway | USD 0.27 mn | 0.04% | USD 0.56 mn | 7.5% |
| 23 | Mexico | USD 0.27 mn | 0.04% | USD 0.70 mn | 9.9% |
| 24 | United Arab Emirates | USD 0.27 mn | 0.04% | USD 0.70 mn | 9.9% |
| 25 | India | USD 0.27 mn | 0.04% | USD 0.85 mn | 11.9% |
| Rest of world | USD 2.7 mn | 0.4% | USD 5.1 mn | 6.6% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Pacira BioSciences
- Heron Therapeutics
- Innocoll Pharmaceuticals
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the extended-action local anaesthetic market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 7.5% is calculated from the resulting values.
The market is divided by product, by setting, by surgery, by administration, by payer. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the extended-action local anaesthetic market?
The global extended-action local anaesthetic market is estimated at USD 630 mn in 2025 and USD 684 mn in 2026.
How fast will the extended-action local anaesthetic market grow?
It is forecast to reach USD 1.4 bn by 2036, a compound annual growth rate of 7.5% from 2026, an increase of USD 725 mn.
Which country is the largest market for extended-action local anaesthetic?
United States is the largest market by revenue at USD 649 mn in 2026, 95.0% of the global total. The three largest countries together hold 96.8%.
Which country is growing fastest?
Among the ten largest markets, Germany is growing fastest at 11.9% a year from 2026 to 2036.
Which extended-action local anaesthetic segment is largest?
In the by product split, Liposomal bupivacaine is the largest segment with 86.0% of 2026 revenue.
Who are the leading extended-action local anaesthetic companies?
Global leaders include Pacira BioSciences, Heron Therapeutics, Innocoll Pharmaceuticals.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Capsule Filling MachineUSD 686 mn · 5.5% CAGR
- Orthopedic Prosthetic AccessoriesUSD 686 mn · 5.3% CAGR
- Laminar Air FlowUSD 689 mn · 6.5% CAGR
- Elderly-Care & Companion RobotsUSD 690 mn · 14.0% CAGR
- Assistive Robots for DisabilityUSD 694 mn · 11.0% CAGR
- Handheld Point-of-Care UltrasoundUSD 660 mn · 9.5% CAGR
- Smart InhalerUSD 713 mn · 15.0% CAGR
- Patient-Specific Surgical Implant DesignUSD 722 mn · 10.5% CAGR
← Epilepsy Monitoring Devices Extracorporeal Membrane Oxygenation Machine →